News

Avella Newsroom

January 1, 1970|
Limiting the Distribution of Oncology Drugs
July 23, 2018| CATEGORIES: limited distribution drugs , Specialty Pharmacy , Oncology

The following article was written by Avella's EVP of Clinical & Quality Assurance, Eric Sredzinski, and published in Specialty Pharmacy Times.

Oncology is already among the top therapeutic classes in specialty pharmacy.1 Experts say that drugs to fight cancer will continue to dominate the next wave of FDA approvals and enter the market at a rapid pace. Yet specifically how these medications are delivered to patients is also expected to evolve over time. This is especially true as manufacturers look to partner with specialty pharmacies that possess highly specific expertise in supporting patients with cancer and their complex treatment regimens.

Avella Releases New Report on Anticipated Specialty Drug Approvals
April 27, 2018| CATEGORIES: Press Release , limited distribution drugs , Specialty Pharmacy

The leading specialty pharmacy has compiled insights about the specialty drug pipeline along with an analysis of the network distribution strategies for these medications.

Phoenix, AZ -- Avella has just announced the release of a 16-page report detailing the specialty drug pipeline, including all of the latest medications expected to receive FDA approval within the coming months. The 2018 Q2 Specialty Medication Pipeline Report provides at-a-glance information about all of these therapies including indications, approval status, anticipated costs, clinical considerations and therapeutic alternatives, among other key data points. It also provides helpful explanations of the various designations and approval processes undertaken by the FDA for specific types of medication such as orphan drugs and breakthrough therapies.

LD Networks Shrinking; What Do You Need to Get In?
April 2, 2018| CATEGORIES: Press Feature , limited distribution drugs , Specialty Pharmacy

Many of today’s most effective specialty drugs are distributed through limited networks of specialty pharmacies, ranging in size from exclusive (one to two pharmacies) through limited small (two to five pharmacies) and limited large (six to 15 pharmacies). A new white paper from Avella Specialty Pharmacy reports that with 79.2% of manufacturers managing their specialty products through a limited distribution (LD) model, these LDs are shrinking even more, consisting of fewer pharmacies than they did just a decade ago.

News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe
Featured Video
Photo of Brian Halligan
Path of a Specialty Prescription
The path of a specialty prescription is complex. This video details each step of the path and the unique offerings of Avella.
Media Contact

Sarah McLeod
800-516-2881  x103
smcleod@activate-health.com

Avella is available to coordinate subject matter expert interviews on a variety of topics including.

  • Specialty pharmacy/pharmacist role
  • Medication adherence and technology
  • Specialty pharmacy pricing considerations

Please contact Sarah McLeod for more information about Avella Specialty Pharmacy.

News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe